FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to production of subunit vaccines against Mycoplasma hyorhinis, and can be used in medicine to prevent a disease caused by Mycoplasma hyorhinis infection, selected from peritonitis, pleurisy, pericarditis and joint swelling. Disclosed is a vaccine composition based on a combination of proteins XylF, DnaK and P72 in combination with an adjuvant. For recombinant production of active vaccine in prokaryotic expression system expression vector is proposed, as well as a method of producing which enables to obtain an active principle of the composition in form of a soluble protein.
EFFECT: invention provides achieving a strong immune response against Mycoplasma hyorhinis.
10 cl, 2 dwg, 7 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR PREVENTING AND TREATING MYCOPLASMA HYORHINIS INFECTION AND METHOD OF PRODUCING SAID COMPOSITION | 2016 |
|
RU2724549C1 |
| SUBUNIT VACCINE AGAINST MYCOPLASMA SPP | 2019 |
|
RU2759427C2 |
| COMPOSITION FOR PREVENTING AND CURING MYCOPLASMA SPP INFECTION | 2013 |
|
RU2646137C2 |
| NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS FOR USING THEM | 2017 |
|
RU2739504C2 |
| RECOMBINANT VECTORS EXPRESSING AVIAN INFLUENZA VIRUS ANTIGENS AND APPLICATIONS THEREOF | 2017 |
|
RU2761869C2 |
| POLYVALENT IMMUNOGENIC COMPOSITION AGAINST HUMAN PAPILLOMAVIRUS | 2020 |
|
RU2806424C2 |
| MYCOBACTERIAL ANTIGEN COMPOSITION | 2015 |
|
RU2702194C2 |
| METHOD FOR CREATING LIVE STRAIN OF ENTEROCOCCUS L3-SARS BASED ON BIOLOGICALLY ACTIVE STRAIN OF E. FAECIUM L3 | 2021 |
|
RU2782529C1 |
| PHARMACEUTICAL COMPOSITION FOR TREATING AND/OR PREVENTING MALIGNANT TUMOUR | 2016 |
|
RU2714205C2 |
| PORCINE PARVOVIRUS | 2015 |
|
RU2817872C2 |
